Latest news with #IBS-C
News18
10-07-2025
- Health
- News18
Forget Supplements - Harvard Doctor Recommends This Fruit for Better Digestion
Why Doctors Are Recommending Two Kiwis a Day for Better Gut Health News18 If you're looking for a simple, natural way to improve digestion and support your gut, doctors say the answer might be as easy as adding two kiwis to your daily diet. Dr. Trisha Pasricha, a gastroenterologist and instructor of medicine, Harvard Medical School, shared in a July 7 piece for The Washington Post that eating two green kiwis a day can significantly benefit your digestive system. According to Dr. Pasricha, 'One kiwi contains 80% or more of an adult's daily vitamin C requirement and offers two to four grams of fibre." Rich in vitamins E and K, antioxidants, and a unique enzyme called actinidin—which helps break down proteins—kiwis are a powerhouse for gut health. And while eating the fuzzy peel isn't necessary, the juicy green inside is packed with benefits. In fact, a 2022 study found that participants who consumed two green kiwis daily for four weeks experienced improved digestion and bowel regularity. On average, people had one to two more complete bowel movements per week. For those struggling with constipation, the benefits included reduced abdominal pain, less straining, and fewer symptoms of indigestion. These findings were further supported by research published in The American Journal of Gastroenterology in June 2023. The study found that daily kiwi consumption led to improved stool consistency, increased bowel movement frequency, and better overall digestive comfort in individuals with constipation and IBS-C (irritable bowel syndrome with constipation). In short, incorporating two kiwis into your diet each day could offer an easy, delicious way to boost gut health and overall wellness—no supplements needed. view comments First Published: July 10, 2025, 12:32 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Yahoo
24-06-2025
- Business
- Yahoo
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT
Ardelyx Inc. (NASDAQ:ARDX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 2, Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Ardelyx Inc. (NASDAQ:ARDX) and set a price target of $10.00. The optimistic rating was based on the company's solid commercial execution in spite of the challenges it faced in Q1. These included the loss of Medicare Part D coverage for Xphozah and the seasonal contraction in the IBS-C market. An aerial view of a pharmaceutical facility, showing the size and scale of the company's operations. The analyst reasoned that Ardelyx Inc. (NASDAQ:ARDX) maintained its guidance for Ibsrela, reflecting solid momentum with anticipated revenues for 2025 between the $240 to 250 million range. Another factor supporting the rating is the management's effective navigation of the Medicare Part D transition for Xphozah. Management also reaffirmed the long-term peak sales targets for Ardelyx Inc. (NASDAQ:ARDX), supporting them with growth drivers such as an expanded sales force and increased clinical conviction among prescribers. Ruiz further reasoned that the company's robust cash position justifies the buy rating, as it offers flexibility for continued business development opportunities and commercial investment. Ardelyx Inc. (NASDAQ:ARDX) develops and commercializes biopharmaceutical products. It is also involved in the development of an innovative platform that discovers new biological mechanisms and pathways to develop efficacious therapies, reducing the drug-drug interactions and side effects of traditional medicines. While we acknowledge the potential of ARDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
06-05-2025
- Business
- Business Upturn
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025 EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patients Ph2b trial in IBS-C initiating in H2 2025 to confirm efficacy Glasgow, Scotland – 6 May 2025. EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical company developing best-in-class therapies for gut health, today presented positive data from its TrIuMPH Phase 2a trial evaluating EBX-102-02, the Company's next-generation oral full-spectrum microbiome product, in patients with irritable bowel syndrome with constipation (IBS-C) at Digestive Disease Week® (DDW) 2025, taking place 3–6 May in San Diego, USA. The multicentre, randomised, double-blind, placebo-controlled TrIuMPH trial evaluated the safety, tolerability, and efficacy of EBX-102-02 in 122 patients with moderate to severe irritable bowel syndrome with constipation (IBS-C) or diarrhoea (IBS-D). Participants were randomised 2:1 to receive 8 capsules of EBX-102-02 on Day 1 and Day 7 or matched placebo, with follow-up through Week 6. Data presented at DDW focused on the IBS-C cohort; results from the IBS-D cohort are expected in Q2 2025. EBX-102-02 was well tolerated, with adverse events primarily mild, self-limiting, and gastrointestinal in nature. Patients receiving EBX-102-02 showed clinically meaningful improvements and favourable trends compared to placebo across multiple endpoints, including the IBS Symptom Severity Score (IBS-SSS), abdominal pain, stool consistency, straining severity, average weekly complete bowel movements, PAC-SYM, and IBS Quality of Life (IBS-QoL). Improvements were observed as early as Week 1 and were sustained through follow-up. Shotgun metagenomic sequencing demonstrated robust strain engraftment, with the microbiome profiles of treated patients shifting toward the composition of the EBX-102-02 product. Highlights from the TrIuMPH trial presented at DDW 2025 included: IBS-SSS: Patients receiving EBX-102-02 showed greater improvement in IBS-SSS than placebo across all measured timepoints, with mean reductions of 78 points compared to 53 in the placebo group by Week 7. Patients receiving EBX-102-02 showed greater improvement in IBS-SSS than placebo across all measured timepoints, with mean reductions of 78 points compared to 53 in the placebo group by Week 7. Abdominal Pain: Mean abdominal pain severity dropped by 14.1 points in the EBX-102-02 group compared to 9.3 in the placebo group by Week 7. There was an improvement in the number of days with reported abdominal pain, with a 2.0 day reduction in the EBX-102-02 compared to 1.1 day reduction in the placebo group at Week 7. Mean abdominal pain severity dropped by 14.1 points in the EBX-102-02 group compared to 9.3 in the placebo group by Week 7. There was an improvement in the number of days with reported abdominal pain, with a 2.0 day reduction in the EBX-102-02 compared to 1.1 day reduction in the placebo group at Week 7. Bristol Stool Form: The weekly average number of stools classified as hard (BSFS 1 or 2) fell from 69% to 30% in the EBX-102-02 group compared to a decrease from 67% to 54% with placebo by Week 3. The weekly average number of stools classified as hard (BSFS 1 or 2) fell from 69% to 30% in the EBX-102-02 group compared to a decrease from 67% to 54% with placebo by Week 3. Complete Bowel Movement Frequency : Patients receiving EBX-102-02 experienced greater improvement in complete bowel movements than those on placebo, with an average increase of over one bowel movement per week in 4 out of 6 follow-up weeks, compared to 2 out of 6 weeks in the placebo group. : Patients receiving EBX-102-02 experienced greater improvement in complete bowel movements than those on placebo, with an average increase of over one bowel movement per week in 4 out of 6 follow-up weeks, compared to 2 out of 6 weeks in the placebo group. Microbiome Shift Toward Product Composition: Faecal microbiota profiles in the EBX-102-02 group shifted toward the composition of the drug product and this effect persisted through Week 7. Dr. James McIlroy MBChB, CEO of EnteroBiotix, commented: 'These positive data in EBX-102-02 for IBS-C represent a significant milestone for EnteroBiotix and for the broader field of microbiome-based therapeutics. EBX-102-02 was well tolerated and demonstrated consistent, clinically meaningful improvements across multiple IBS symptoms and measurements of quality of life. The observed microbial engraftment reinforces our confidence our full-spectrum approach. We look forward to advancing EBX-102-02 into a Ph2b trial later this year and were pleased to discuss these data with our Scientific Advisory Board during the Conference.' About EnteroBiotix EnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®. About EBX-102-02 EBX-102-02 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the Company's proprietary AMPLA™ technology, EBX-102-02 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including irritable bowel syndrome (IBS). Media contacts EnteroBiotixDr James McIlroy, CEO [email protected]
Yahoo
30-04-2025
- Business
- Yahoo
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
BOSTON, April 30, 2025--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland. We routinely post information that may be important to investors on our website at In addition, follow us on X and on LinkedIn. View source version on Contacts Company contact: Greg Martinigmartini@ Investors: Precision AQ (formerly Stern Investor Relations)Stephanie Sign in to access your portfolio
Business Wire
30-04-2025
- Business
- Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7 th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS ® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland. We routinely post information that may be important to investors on our website at In addition, follow us on X and on LinkedIn.
